aminocandin: a lipopeptide belonging to the echinocandin class of antifungal compounds; inhibits glucan synthase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
aminocandin : A member of the family of echinocandins that shows broad-spectrum in vitro activity against Aspergillus and Candida spp. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 11679714 |
| CHEBI ID | 84073 |
| SCHEMBL ID | 8239340 |
| MeSH ID | M0495540 |
| Synonym |
|---|
| aminocandin |
| DB05128 |
| CHEBI:84073 |
| n-[(2r,6s,9s,14as,15s,16s,20s,23s,25as)-11-[(2-aminoethyl)amino]-2,15-dihydroxy-6-[(1r)-1-hydroxyethyl]-23-[(1r)-1-hydroxy-2-(4-hydroxyphenyl)ethyl]-20-(hydroxymethyl)-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1h-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13 |
| SCHEMBL8239340 |
| 227472-48-2 |
| HY-P0068 |
| CS-0015488 |
| n-[(3s,6s,9s,11r,15s,18s,24s,25s,26s)-20-(2-aminoethylamino)-11,25-dihydroxy-15-[(1r)-1-hydroxyethyl]-6-[(1r)-1-hydroxy-2-(4-hydroxyphenyl)ethyl]-3-(hydroxymethyl)-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-y |
| DTXSID301336192 |
Aminocandin is a new representative of the echinocandins. It could potentially affect the cellular morphology and metabolic status of Candida albicans cells within biofilms.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Aminocandin is an investigational echinocandin with excellent activity against Candida species, including Candida albicans and Candida tropicalis. " | ( Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. Bocanegra, R; Brzankalski, GE; Fothergill, AW; Graybill, JR; Najvar, LK; Pattterson, TF; Rinaldi, MG; Wiederhold, NP, 2008) | 2.15 |
| "Aminocandin is a new representative of the echinocandins that could potentially affect the cellular morphology and metabolic status of Candida albicans cells within biofilms. " | ( The effect of aminocandin (HMR 3270) on the in-vitro adherence of Candida albicans to polystyrene surfaces coated with extracellular matrix proteins or fibronectin. Borgonovi, M; Cateau, E; Imbert, C; Levasseur, P, 2007) | 2.14 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Treatment with aminocandin, given iv twice a week, resulted in 100% survival. " | ( Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis. Ghannoum, MA; Kim, HG; Long, L, 2007) | 1.07 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Very little is known of these pharmacodynamic relationships for the new echinocandin class of compounds." | ( In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Andes, D; Bryskier, A; Conklin, R; Lowther, J; Marchillo, K; Stamstad, T, 2003) | 0.32 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Reduced toxicity, enhancement of bioavailability and counteraction of resistance are features desired by clinicians." | ( Newer antifungal agents. Türel, O, 2011) | 0.37 |
Aminocandin, CAS and micafungin (2-10mg/kg) were all effective at prolonging survival. Some impact on reducing culture burdens, even with alternate-day dosing (4mg/ kg)
| Role | Description |
|---|---|
| antiinfective agent | A substance used in the prophylaxis or therapy of infectious diseases. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| echinocandin | Any one of a family of large lipopeptides that are inhibitors of the enzyme 1,3-beta-glucan synthase, thus damaging fungal cell walls. Echinocandins are fungicidal against most Candida spp and fungistatic against Aspergillus spp. |
| homodetic cyclic peptide | A homodetic cyclic peptide is a cyclic peptide in which the ring consists solely of amino-acid residues in peptide linkages. |
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.99) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (18.18%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (81.82%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||